[1] Adinolfi LE, Zampino R, Restivo L, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol, 2014, 20(13):3410-3417. [2] Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation, 2007, 115(4):459-467. [3] Hsu TH, Tsui PH, Yu WT, et al. Cutoff values of acoustic radiation force impulse two-location measurements in different etiologies of liver fibrosis. J Med Ultrasound, 2019, 27(3):130-134. [4] Tseng CH, Chang CY, Mo LR, et al. Acoustic radiation force impulse elastography with APRI and FIB-4 to identify significant liver fibrosis in chronic hepatitis B patients. Ann Hepatol, 2018, 17(5):789-794. [5] Wu SD, Ding H, Liu LL, et al. Longitudinal monitoring of liver stiffness by acoustic radiation force impulse imaging in patients with chronic hepatitis B receiving entecavir. Clin Res Hepatol Gastroenterol, 2018, 42(3):227-236. [6] Demirci R, Sevinc C. The relationship between carotid intima media thickness, inflammation and GLA rich protein levels in chronic kidney disease. Int J Gen Med, 2021, 14:5119-5126. [7] Zhang Z, Liu Y, Zhang Y, et al. The association between low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio cholesterol ratio and thickened carotid intima-media thickness: a case-control study. Vascular, 2021, 17085381211035282. [8] Qian C, Sun Y, Jiang J. Diagnostic values of epicardial adipose tissue thickness with right common carotid artery elasticity and intima-media thickness for middle-aged and elderly patients with coronary heart disease. Int J Gen Med, 2021, 14:633-639. [9] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志, 2016, 19(3): 389-400. [10] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2015年更新版). 实用肝脏病杂志, 2016, 19(4):后插9-后插26. [11] 包中涛, 古立娟, 刘景丰, 等. 声脉冲辐射力技术鉴别诊断肝脏局灶性病变. 中华肝脏病杂志, 2016, 24(2): 123-126. [12] Lankarani KB, Mahmoodi M, Lotfi M, et al. Common carotid intima-media thickness in patients with non-alcoholic fatty liver disease: a population-based case-control study. Korean J Gastroenterol, 2013, 62(6): 344-351. [13] Cheng CH, Chu CY, Chen HL, et al. Virus elimination by direct-acting antiviral agents impacts glucose homeostasis in chronic hepatitis C patients. Front Endocrinol (Lausanne), 2022, 12:799382. [14] Mazzaro C, Quartuccio L, Adinolfi LE, et al. A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy. Viruses, 2021, 13(11):2249. [15] Bailey AL, Al-Adwan S, Sneij E, et al. Atherosclerotic cardiovascular disease in individuals with hepatitis C viral infection. Curr Cardiol Rep, 2021, 23(5):52. |